<table id="ID1142" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 2: Clinically Relevant Interactions Affecting Drugs Co-Administered with Rabeprazole Sodium Delayed-Release Tablets</caption>
<col width="21%"></col>
<col width="79%"></col>
<tbody>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="bold">Antiretrovirals </content>
<br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">: </content>
<br/>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">The effect of PPI on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. <br/>
<br/>•  Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with rabeprazole may reduce antiviral effect and promote the<br/> development of drug resistance. <br/>
<br/>•  Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with rabeprazole may increase toxicity<content stylecode="italics">.</content>
<br/>
<br/>•  There are other antiretroviral drugs which do not result in clinically relevant interactions with rabeprazole. <br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Toprule" valign="middle">
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Toprule" valign="top">Rilpivirine-containing products: Concomitant use with rabeprazole sodium delayed-release tablets are contraindicated [see CONTRAINDICATIONS (<linkhtml href="#ID944">4</linkhtml>)]. See prescribing information.  </td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule" valign="middle">
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule" valign="top">
<content stylecode="underline">Atazanavir</content>
<content stylecode="underline">: </content>See prescribing information for atazanavir for dosing information. <br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule" valign="middle">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule" valign="top">
<content stylecode="underline">Nelfinavir</content>
<content stylecode="underline">: </content>Avoid concomitant use with rabeprazole sodium delayed-release tablets. See prescribing information for nelfinavir. <br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule" valign="middle">
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule" valign="top">
<content stylecode="underline">Saquinavir</content>
<content stylecode="underline">: </content>See the prescribing information for saquinavir and monitor for potential saquinavir toxicities. <br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule" valign="middle">
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule" valign="top">
<content stylecode="underline">Other </content>
<content stylecode="underline">antiretrovirals</content>
<content stylecode="underline">: </content>See prescribing information. <br/>
</td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="bold">Warfarin </content>
<br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">: </content>
<br/>
<content stylecode="bold">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Increased INR and prothrombin time in patients receiving PPIs, including rabeprazole, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal  bleeding and even death [see WARNINGS AND PRECAUTIONS (<linkhtml href="#ID955">5.2</linkhtml>)].  </td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Monitor INR and prothrombin time. Dose adjustment of warfarin may be needed to maintain target INR range. See prescribing information for warfarin. <br/>
</td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="bold">Methotrexate </content>
<br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">: </content>
<br/>
<content stylecode="bold">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Concomitant use of rabeprazole with methotrexate (primarily at high dose) may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate,  possibly leading to methotrexate toxicities. No formal drug interaction studies of methotrexate with PPIs have been conducted [see WARNINGS AND PRECAUTIONS (<linkhtml href="#ID1148">5.9</linkhtml>)].  </td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">: </content>
<br/>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">A temporary withdrawal of rabeprazole sodium delayed-release tablets may be considered in some patients receiving high dose methotrexate administration. <br/>
</td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="bold">Digoxin </content>
<br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Potential for increased exposure of digoxin [see CLINICAL PHARMACOLOGY (<linkhtml href="#ID1028">12.3</linkhtml>)].  </td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Monitor digoxin concentrations. Dose adjustment of digoxin may be needed to maintain therapeutic drug concentrations. See prescribing information for digoxin. <br/>
</td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="bold">Drugs </content>
<content stylecode="bold">Dependent </content>
<content stylecode="bold">on </content>
<content stylecode="bold">Gastric </content>
<content stylecode="bold">pH </content>
<content stylecode="bold">for </content>
<content stylecode="bold">Absorption </content>
<content stylecode="bold">(</content>
<content stylecode="bold">e</content>
<content stylecode="bold">.</content>
<content stylecode="bold">g</content>
<content stylecode="bold">., </content>
<content stylecode="bold">iron </content>
<content stylecode="bold">salts</content>
<content stylecode="bold">, </content>
<content stylecode="bold">erlotinib</content>
<content stylecode="bold">, </content>
<content stylecode="bold">dasatinib</content>
<content stylecode="bold">, </content>
<content stylecode="bold">nilotinib</content>
<content stylecode="bold">, </content>
<content stylecode="bold">mycophenolate </content>
<content stylecode="bold">mofetil</content>
<content stylecode="bold">, </content>
<content stylecode="bold">ketoconazole</content>
<content stylecode="bold">, </content>
<content stylecode="bold">itraconazole</content>
<content stylecode="bold">) </content>
<br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Rabeprazole can reduce the absorption of drugs due to its effect on reducing intragastric acidity. <br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">: </content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Mycophenolate mofetil (MMF): Co-administration of PPIs in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, <br/>mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH. The clinical relevance of reduced MPA exposure on organ rejection has not been established in <br/>transplant patients receiving PPIs and MMF. Use rabeprazole sodium delayed-release tablets with caution in transplant patients receiving MMF. <br/>
<br/>See the prescribing information for other drugs dependent on gastric pH for absorption. <br/>
</td>
</tr>
<tr>
<td align="justify" colspan="2" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="bold">Combination </content>
<content stylecode="bold">Therapy </content>
<content stylecode="bold">with </content>
<content stylecode="bold">Clarithromycin </content>
<content stylecode="bold">and </content>
<content stylecode="bold">Amoxicillin </content>
<br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">: </content>
<content stylecode="bold">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Concomitant administration of clarithromycin with other drugs can lead to serious adverse reactions, including potentially fatal arrhythmias, and are contraindicated.<br/>
<br/>Amoxicillin also has drug interactions. <br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="middle">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">: </content>
<content stylecode="italics">
<br/>
</content>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">See <linkhtml href="#ID944">CONTRAINDICATIONS</linkhtml> and <linkhtml href="#ID949">WARNINGS AND PRECAUTIONS</linkhtml> in prescribing information for clarithromycin.   See <linkhtml href="#ID1137">DRUG INTERACTIONS</linkhtml> in prescribing information for amoxicillin.  </td>
</tr>
</tbody>
</table>